Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. MU
2. SPCX
3. APTX:CN
4. SPY
5. IQMX
6. EROC
7. MSTR
8. NVDA
9. RIVN
10. TSLA

Go back to Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358

Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology

November 10, 2019 11:00 AM EST

SAN FRANCISCO, Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic inflammatory conditions.

The data, which were presented at the 2019 Annual Meeting of the American College of Rheumatology in Atlanta, show that treatment with NKTR-358 led to a marked and selective dose-dependent expansion in the numbers and proliferative capacity of FoxP3+CD25bright Treg cells, and a measurable activation of Treg cells.... More